|
| 36912782 | Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners. | Mol Cancer Ther | 2023 |
| 34570508 | Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. | J Med Chem | 2021 |
| 34647738 | Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. | J Med Chem | 2021 |
| 32988967 | AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. | Clin Cancer Res | 2020 |
| 33335676 | Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833. | ACS Med Chem Lett | 2020 |
| 33306391 | Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. | J Med Chem | 2020 |
| 32910656 | Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. | J Med Chem | 2020 |
| 31620239 | Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry. | ACS Med Chem Lett | 2019 |
| 29266803 | Structure-Based Design of Selective Noncovalent CDK12 Inhibitors. | ChemMedChem | 2018 |
| 29486970 | Bicyclo((aryl)methyl)benzamides as inhibitors of GlyT1. | Bioorg Med Chem Lett | 2018 |
| 27994749 | Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. | ACS Med Chem Lett | 2016 |
| 26597534 | Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors. | Bioorg Med Chem Lett | 2016 |
| 24881567 | Towards the next generation of dual Bcl-2/Bcl-xL inhibitors. | Bioorg Med Chem Lett | 2014 |
| 21295468 | Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). | Bioorg Med Chem Lett | 2011 |
| 21645511 | Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase. | Eur J Pharmacol | 2011 |
| 20637614 | Identification of N-(2-(azepan-1-yl)-2-phenylethyl)-benzenesulfonamides as novel inhibitors of GlyT1. | Bioorg Med Chem Lett | 2010 |
| 19767451 | Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation. | Mol Pharmacol | 2009 |
| 18054227 | Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. | Bioorg Med Chem Lett | 2008 |
| 17418570 | CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. | Bioorg Med Chem Lett | 2007 |
| 17933529 | Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. | Bioorg Med Chem Lett | 2007 |
| 17315987 | Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor. | J Med Chem | 2007 |
| 15026042 | Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists. | Bioorg Med Chem Lett | 2004 |
| 12067561 | CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. | Bioorg Med Chem Lett | 2002 |